Bristol-Myers performing well ahead of Celgene acquisition

25 July 2019
bristol-myers-squibb-big

In a day of mixed news for Bristol-Myers Squibb (NYSE: BMY), the company revealed an upbeat second-quarter 2019 results statement, fighting earlier pre-market declines on the back of a  trial failure in lung cancer.

The New York-based cancer specialist managed to increase second-quarter revenues to $6.3 billion, up 10% on the same period from 2018, and posted second-quarter earnings per share (EPS) of $0.87, following Generally Accepted Accounting Principles (GAAP).

The strong results were driven largely by robust sales for Eliquis (apixaban) and Opdivo (nivolumab) as well as a good performance across the portfolio. Results in the USA were particularly encouraging, with a revenue increase of 14%, to $3.7 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology